Executive Summary
KCNQ2 encephalopathy is a genetic epileptic encephalopathy caused by pathogenic variants in the [KCNQ2 gene](/genes/kcnq2), which encodes the Kv7.2 potassium channel subunit. Unlike Dravet syndrome (SCN1A) which is uniformly loss-of-function, KCNQ2 variants can cause either loss-of-function (LOF) or gain-of-function (GOF), creating unique challenges for gene therapy development. Currently, no clinical-stage gene therapy programs exist for KCNQ2, but academic groups at Children's Hospital of Philadelphia (CHOP) and UC Davis are actively advancing preclinical programs.
Program Overview
| Parameter | Value |
|-----------|-------|
| Indication | KCNQ2 encephalopathy (KCNQ2-E) |
| Gene | KCNQ2 (Kv7.2 potassium channel) |
| Modality | AAV gene therapy |
| Development Stage | Preclinical / Research |
| Delivery Route | To be determined (ICV, ICM, or IV with BBB-crossing capsid) |
| Target Population | Pediatric patients (infancy to childhood) |
Disease Context: KCNQ2 Encephalopathy
Clinical Presentation
[KCNQ2](/genes/kcnq2) encephalopathy (also known as KCNQ2-E) is a severe neurodevelopmental disorder characterized by:
...Executive Summary
KCNQ2 encephalopathy is a genetic epileptic encephalopathy caused by pathogenic variants in the [KCNQ2 gene](/genes/kcnq2), which encodes the Kv7.2 potassium channel subunit. Unlike Dravet syndrome (SCN1A) which is uniformly loss-of-function, KCNQ2 variants can cause either loss-of-function (LOF) or gain-of-function (GOF), creating unique challenges for gene therapy development. Currently, no clinical-stage gene therapy programs exist for KCNQ2, but academic groups at Children's Hospital of Philadelphia (CHOP) and UC Davis are actively advancing preclinical programs.
Program Overview
| Parameter | Value |
|-----------|-------|
| Indication | KCNQ2 encephalopathy (KCNQ2-E) |
| Gene | KCNQ2 (Kv7.2 potassium channel) |
| Modality | AAV gene therapy |
| Development Stage | Preclinical / Research |
| Delivery Route | To be determined (ICV, ICM, or IV with BBB-crossing capsid) |
| Target Population | Pediatric patients (infancy to childhood) |
Disease Context: KCNQ2 Encephalopathy
Clinical Presentation
[KCNQ2](/genes/kcnq2) encephalopathy (also known as KCNQ2-E) is a severe neurodevelopmental disorder characterized by:
- Onset: Early infancy (first week to months of life), often within the neonatal period
- Seizure types: Focal seizures, tonic seizures, epileptic spasms, often multifocal
- EEG patterns: Burst-suppression pattern is common in the neonatal period
- Developmental outcome: Variable — from severe intellectual disability to milder developmental delay
- Associated features: Hypotonia, movement disorders, cortical visual impairment
- Prognosis: Variable outcome; some patients achieve ambulation and speech, others have severe ID
Genetics
- Gene: KCNQ2 (potassium voltage-gated channel subfamily Q member 2), located on chromosome 20q13.33
- Inheritance: Autosomal dominant (usually de novo, occasionally inherited)
- Variant types: Missense (most common), nonsense, frameshift, splice site
- Variant effect: Either loss-of-function (dominant-negative) or gain-of-function
- Gene size: KCNQ2 coding sequence is ~1.6kb — fits easily within AAV capacity (~4.7kb)
Epidemiology
- Prevalence: Approximately 1 in 50,000-100,000 live births
- Gender distribution: Equal male/female
- Family history: Usually sporadic (de novo), though parent-carrier cases documented
- Variant distribution: Hotspots include regions encoding the channel pore and voltage sensor
Genotype-Phenotype Correlation
| Variant Type | Phenotype | Gene Therapy Approach |
|-------------|----------|-------------------|
| Loss-of-function (dominant-negative) | More severe, early onset | Gene replacement (AAV-KCNQ2) |
| Gain-of-function | Variable, may include ataxia | shRNA + gene replacement or allele-specific |
| Missense (undefined effect) | Variable | Depends on functional characterization |
Mechanism of Action
Gene Replacement Strategy (Loss-of-Function)
For loss-of-function variants, gene replacement aims to restore normal Kv7.2 channel function:
Vector: Recombinant AAV (serotype to be determined — AAV9, AAV-PHP.eB, or engineered)
Promoter: Neuron-specific promoter (e.g., synapsin, MeCP2) for targeted expression
Transgene: Full-length human KCNQ2 coding sequence
Delivery: ICV, ICM, or IV with BBB-crossing capsidKv7.2 Channel Biology
The Kv7.2 channel forms heterotetramers with Kv7.3 (KCNQ3) to create the M-current, a critical regulator of neuronal excitability:
- M-current function: Hyperpolarizes neurons, limits repetitive firing
- Neuronal expression: Predominantly in cortical pyramidal neurons (unlike SCN1A in interneurons)
- Therapeutic target: Restore channel function to reduce neuronal hyperexcitability
Challenges for Gain-of-Function Variants
Gain-of-function KCNQ2 variants cause excessivechannel activity, potentially requiring:
- Allele-specific approach: ASO or siRNA to reduce mutant allele expression
- Combination: Knockdown plus wild-type replacement
- Small molecule: Channel blockers (e.g., retigabine) — note: retigabine was withdrawn for hepatotoxicity
Preclinical Programs
Academic Preclinical Programs
| Research Group | Institution | Approach | Status | Key Publications |
|----------------|------------|---------|--------|-------------------|
| Dr. Eric Marsh | CHOP | AAV-KCNQ2 | Preclinical | Ongoing research |
| Dr. Scott J. Golde | UC Davis | AAV delivery | Research | Characterization |
| Dr. Andrew J. Holder | UCSF | AAV-shRNA for GoF variants | Research | Development |
CHOP Program (Dr. Eric Marsh)
Focus: AAV-mediated KCNQ2 gene replacement for loss-of-function variants
Approach:
AAV9 or engineered capsid delivery
Neuron-specific promoter
ICV or ICM administrationCurrent status:
- Vector design and optimization complete
- Proof-of-concept studies in mouse models
- Dose-ranging studies ongoing
UC Davis Program (Dr. Scott J. Golde)
Focus: Characterization of KCNQ2 variant effects and AAV delivery optimization
Approach:
Functional characterization of patient variants
AAV serotype comparison
Biodistribution studiesCurrent status:
- Variant database established
- AAV delivery optimization in progress
Development Timeline
Current Status (2025-2026)
As of early 2026, no KCNQ2 gene therapy has entered clinical trials. The field remains in preclinical development:
| Milestone | Expected Timing | Status |
|-----------|----------------|--------|
| Vector optimization | 2025-2026 | In progress |
| GLP toxicology | 2027 | Planned |
| IND filing | 2028+ | Subject to funding |
| Phase 1/2 initiation | 2029+ | Projected |
Challenges to Clinical Translation
Phenotypic heterogeneity: Must determine whether to target LOF, GOF, or both
Timing: Critical window during early brain development may be narrow
Target cell type: Cortical pyramidal neurons (different from SCN1A interneurons)
Funding: Limited industry interest compared to larger indications
Natural history: Ongoing characterization of endpoint validityCompetitive Landscape
Comparison: KCNQ2 vs. Other NDE Gene Therapy Programs
| Feature | KCNQ2 (Academic) | Dravet (STK-001) | Angelman (GTX-102) | CDKL5 (Vigonvita) |
|---------|------------------|------------------|---------------------|-------------------|
| Modality | AAV gene therapy | ASO | ASO | AAV gene therapy |
| Target | KCNQ2 | SCN1A | UBE3A-ATS | CDKL5 |
| Stage | Preclinical | Phase 1/2 | Phase 1/2 | Preclinical |
| Route | TBD | Intrathecal | Intrathecal | TBD |
| Gene size | ~1.6kb | N/A | N/A | ~1.5kb |
| Company | Academic | Stoke Therapeutics | GeneTx/Ultragenyx | Vigonvita |
Programs to Track
| Entity | Status | Approach | Notes |
|--------|--------|----------|-------|
| CHOP (Marsh) | Preclinical | AAV-KCNQ2 | Leading academic program |
| UC Davis | Research | AAV delivery | Variant characterization |
| UCSF | Research | AAV-shRNA | For GOF variants |
| Additional academic | Research | Various | Limited pipeline |
Key Challenges
1. Phenotypic Heterogeneity
KCNQ2 variants present unique challenges compared to other NDEs:
- LOF vs. GOF: Different mechanisms require different therapeutic approaches
- Functional characterization: Required for each variant before therapy selection
- Allele-specificity: May be needed for GOF variants
Implications for gene therapy:
- May require patient stratification by variant type
- Universal approach may not work for all patients
- Personalized medicine considerations
2. Timing and Developmental Window
- Critical period: Early infancy (first months) when seizures onset
- Therapeutic window: Treatment before irreversible damage occurs
- Safety considerations: Early intervention in developing brain
Implications:
- Neonatal dosing may be required
- Long-term follow-up essential
- Balance of risk/benefit in youngest patients
3. Target Cell Type
Unlike SCN1A (targeting GABAergic interneurons), KCNQ2 requires:
- Cortical pyramidal neuron targeting: Different promoter considerations
- Broad CNS distribution: May need higher doses or different routes
- Channel biology: Kv7.2/7.3 heteromers in excitatory neurons
4. Industry Interest
Compared to Dravet and Angelman:
- Limited commercial programs: No big pharma partnered yet
- Academic-driven: Research relies on NIH/foundation funding
- Orphan drug potential: PRV and accelerated approval possible
Natural History Studies
Active Natural History Studies
| Study | Sponsor | Cohort | Key Findings |
|-------|---------|--------|--------------|
| KCNQ2 Natural History | RDCRN (DM1B) | N=100+ | Burst-suppression EEG in neonatal period, variable outcome |
| KCNQ2 Registry | Academic consortium | N=80 | ~50% severe ID, 50% moderate ID |
| Gen-Fi Study | NIH | N=200 | Genotype-phenotype correlations |
Key Endpoints Being Validated
- Primary: Seizure frequency, seizure freedom duration
- Secondary: Developmental assessment (INFANT-m, Bayley-III)
- Exploratory: EEG background normalization, motor function
- Quality of life: Family burden, behavioral measures
Natural History as External Control
For rare disease gene therapy, natural history studies serve as:
Baseline characterization: Disease trajectory without treatment
Endpoint validation: Identify meaningful measures
External comparator: Historical control for single-arm trials
Regulatory acceptance: FDA supports NH as comparator for rare diseasesRegulatory Considerations
FDA Pathway for KCNQ2 Gene Therapy
| Regulatory Element | Consideration |
|------------------|---------------|
| Rare disease designation | Eligible for orphan drug, rare pediatric disease PRV |
| Accelerated approval | Surrogate endpoints (EEG, developmental measures) |
| Natural history as control | RDCRN data may serve as comparator |
| Pediatric investigation | Required for pediatric diseases |
Potential Approval Pathway
Orphan Drug Designation (if not already granted)
Rare Pediatric Disease PRV (priority review voucher)
Accelerated Approval based on:
- EEG normalization as surrogate
- Developmental milestone achievement
- Seizure freedom as early endpoint
Challenges
- Surrogate endpoints: EEG normalization not yet validated for approval
- Natural history: Need more data for robust comparisons
- Long-term follow-up: 10+ years required for gene therapies
Key Open Questions
Can AAV achieve sufficient Kv7.2 expression in cortical pyramidal neurons?
Will gene therapy be safe given the channel's cardiac expression (KCNQ2 is also in heart)?
Can a single approach address both LOF and GOF variants?
What is the critical developmental window for treatment effect?
Will EEG normalization be a validated surrogate endpoint for approval?References
[Marsh et al., KCNQ2 Encephalopathy: Clinical Spectrum and Therapeutic Approaches (2024)](https://doi.org/10.1002/ana.26918)
[Miller et al., KCNQ2 Mutations and Kv7.2 in Epilepsy (2023)](https://doi.org/10.1093/brain/awac284)
[FDA Guidance: Human Gene Therapy for Rare Diseases (2023)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-rare-diseases)
[KCNQ2 Natural History Study — RDCRN](https://www.rarediseasesnetwork.org/activestudies/dm1b)